Oragenics Regains NYSE Compliance Following $16.5 Million Funding Round

Oragenics Inc. (NYSE American: OGEN) has successfully regained full compliance with NYSE American's continued listing standards, marking a significant corporate milestone for the clinical-stage biotechnology company. Effective October 20, 2025, the exchange confirmed the company's compliance with Section 1003(a)(iii), removing the below-compliance indicator and restoring Oragenics to the roster of compliant issuers. This regulatory achievement follows the company's successful completion of a $16.5 million public offering of Series H Convertible Preferred Stock on July 2, 2025, which substantially strengthened the company's financial position.

CEO Janet Huffman emphasized the broader significance of this development, stating that regaining compliance represents more than just meeting regulatory requirements. According to Huffman, this achievement reflects the company's commitment to transparency, financial discipline, and restoring investor confidence in the organization. The restored compliance status comes at a critical juncture for Oragenics as it advances its lead candidate, ONP-002, through key clinical development phases.

The $16.5 million funding round has positioned Oragenics to accelerate development of ONP-002, which aims to become the first FDA-approved treatment for concussion. The capital infusion has restored stockholder equity and provides necessary resources to fund the therapeutic candidate through important Phase II milestones currently underway in Australia. Additionally, the funding supports preparation for upcoming Phase IIb trials planned for the United States market.

Oragenics is developing brain-targeted therapeutics using proprietary intranasal delivery technology that enables targeted, non-invasive treatment for brain-related conditions. The company's platform technology holds potential for addressing various neurological conditions beyond concussion, including neurodegenerative diseases and central nervous system disorders. The full press release detailing these developments is available at https://ibn.fm/bd7Im.

Investors and stakeholders can access the latest news and updates relating to OGEN through the company's dedicated newsroom at https://ibn.fm/OGEN. The restoration of NYSE compliance, combined with the substantial funding round, represents a pivotal moment for Oragenics as it progresses its innovative neurological treatment platform through critical clinical development stages while maintaining its standing as a compliant publicly-traded company.